Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS

Chest. 2003 Jul;124(1):406-10. doi: 10.1378/chest.124.1.406.

Abstract

A 49-year-old man with cirrhosis due to hepatitis C virus developed interstitial pneumonitis documented by surgical lung biopsy specimen evaluation after two weekly doses of pegylated interferon-alpha(2)b in combination with ribavirin. He developed ARDS and died after 26 days of hospitalization from multisystem organ failure. This case suggests that interstitial pulmonary disease can occur with pegylated interferon-alpha(2)b therapy.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Biopsy
  • Hepatitis C / drug therapy
  • Humans
  • Interferon alpha-2
  • Interferon-alpha* / adverse effects*
  • Interferon-alpha* / therapeutic use
  • Lung / diagnostic imaging
  • Lung / pathology
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / diagnosis
  • Male
  • Middle Aged
  • Polyethylene Glycols*
  • Radiography
  • Recombinant Proteins
  • Respiratory Distress Syndrome / chemically induced*
  • Respiratory Distress Syndrome / diagnosis
  • Ribavirin / adverse effects*
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2b
  • peginterferon alfa-2a